Patent ID: 11897969
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of reducing cardiomyocyte death associated with reperfusion-dependent oxidized phospholipid (OxPL) generation in a subject at risk thereof following a cardiac ischemic event, comprising
administering a therapeutically effective amount of an antibody or antibody fragment that specifically binds to a phosphocholine headgroup of an oxidized phospholipid to the subject, wherein the antibody or antibody fragment comprises: a variable heavy chain domain (VH) that includes complementarity determining regions (CDRs) comprising amino acid sequences that are at least 95% identical to each of SEQ ID NO:6, 7, and 8; and a variable light chain domain (VL) that includes CDRs comprising amino acid sequences that are at least 95% identical to each of SEQ ID NO:9 or 12, 10, and 11, wherein the antibody or antibody fragment is administered within 10 hours after the ischemic event.